AtaiBeckley Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ATAI Nasdaq 2830 www.ataibeckley.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AtaiBeckley Inc.

Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers - Apr 14th, 2026 9:18 am
AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs - Apr 12th, 2026 3:46 pm
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003 - Apr 8th, 2026 6:40 am
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Apr 8th, 2026 4:00 am
Deutsche Bank Confident of AtaiBeckley Inc. (ATAI) Growth Prospects on Psychedelic Medicines - Apr 6th, 2026 3:02 pm
AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support - Mar 29th, 2026 11:02 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Mar 29th, 2026 8:25 am
AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts - Mar 27th, 2026 9:25 am
H.C. Wainwright Bullish on AtaiBeckley (ATAI) - Mar 27th, 2026 12:44 am
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003? - Mar 25th, 2026 12:11 pm
AtaiBeckley added to major US indices, increasing reach among passive investors - Mar 24th, 2026 6:36 am
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst - Mar 24th, 2026 4:00 am
Assessing AtaiBeckley (ATAI) Valuation As Strong Long Term Returns Contrast With Heavy Losses - Mar 19th, 2026 12:05 am
AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003 - Mar 17th, 2026 7:09 am
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation - Mar 17th, 2026 4:00 am
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day - Mar 10th, 2026 8:45 am
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - Mar 10th, 2026 4:00 am
Sector Update: Health Care Stocks Higher Late Afternoon - Mar 9th, 2026 1:51 pm
AtaiBeckley’s FDA Backing And Trial Data Reframe Mental Health Upside And Risk - Mar 9th, 2026 6:11 am
AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 - Mar 8th, 2026 10:57 am